MassDevice

Edwards shares superior long-term outcomes from TAVR studies

Edwards Lifesciences (NYSE: EW) today announced new data demonstrating long-term benefits with its Sapien heart valve system.
The New England Journal of Medicine

Transcatheter or Surgical Aortic-Valve Replacement in Low-Risk Patients at 7 Years

Five-year data from the PARTNER 3 trial showed that among low-risk patients with severe, symptomatic aortic stenosis, ...
MassDevice

Medtronic launches new guidewire to support TAVR procedures

Medtronic (NYSE: MDT) today announced the launch of its Stedi extra support guidewire for use with its Evolut TAVR platform.
TCTMD

PARTNER 3 at 7 Years: Stable Outcomes, No Signs of Valve Failure With TAVI

The data are largely in line with those seen at 5 years, but the follow-up reassures there’s no concern about valve ...
Medscape

HIV/AIDS

Physicians and their patients report that engagement in an HIV-based community rivals drug effectiveness in the ongoing efforts to curtail an epidemic. Confronting the HIV Epidemic: There's an App for ...